JPS6345792B2 - - Google Patents
Info
- Publication number
- JPS6345792B2 JPS6345792B2 JP60169170A JP16917085A JPS6345792B2 JP S6345792 B2 JPS6345792 B2 JP S6345792B2 JP 60169170 A JP60169170 A JP 60169170A JP 16917085 A JP16917085 A JP 16917085A JP S6345792 B2 JPS6345792 B2 JP S6345792B2
- Authority
- JP
- Japan
- Prior art keywords
- brain
- calcium
- infants
- dried
- marrow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004556 brain Anatomy 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 229960005069 calcium Drugs 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000004227 calcium gluconate Substances 0.000 claims description 5
- 229960004494 calcium gluconate Drugs 0.000 claims description 5
- 235000013927 calcium gluconate Nutrition 0.000 claims description 5
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 229960004256 calcium citrate Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 239000001362 calcium malate Substances 0.000 claims 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims 1
- 229940016114 calcium malate Drugs 0.000 claims 1
- 235000011038 calcium malates Nutrition 0.000 claims 1
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 claims 1
- 239000001427 calcium tartrate Substances 0.000 claims 1
- 235000011035 calcium tartrate Nutrition 0.000 claims 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 9
- 235000013305 food Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000004641 brain development Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- -1 calcium gluconate Chemical compound 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
産業上の利用分野
本発明は特に乳幼児の脳の発育に好影響を及ぼ
す脳髄粉末であつて食用にも薬用にも供され得る
該製品の製造法に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a method for producing a brain marrow powder that has a favorable effect on the brain development of infants and young children and can be used for both edible and medicinal purposes.
従来の技術
ヒトの脳は誕生後３才迄の間に急速に発育し、
５才以上では脳重量の増加は極めて遅くなるとさ
れている。ヒトの脳は他の臓器と異なり、乾燥重
量を基準として約60％が脂質で占められているこ
とがよく知られている。また脳神経の外側を保護
している髄鞘（ミエリン）にこの脂質が重要な構
成要素として使用されており、高等動物では脳や
脊髄が発育すればする程髄鞘が増加することもよ
く知られている。しかもこの髄鞘形成と学習能力
とは相互に深い関係にあることが動物試験の結果
から示唆されている〔塚田裕三：日本医事新報昭
和50年第2684号第126〜127頁；中脩三：脳髄の機
能と教育（昭和46年慶応通信発行）第200〜201
頁〕。この脳髄の主成分である脂質は植物中には
見出すことのできない炭素数の長い脂肪酸を極め
て豊富に含んでおり、特にホスフアヂジルエタノ
ールアミンの構成成分の脂肪酸の40〜50％はヒト
に特有のものであることが確認されている〔M.
Crawford著、山口彦之ほか訳：食生活と文明
（佑学社）第40〜46頁（1980年）〕。ヒトの母乳は
牛乳に殆んど検出できない炭素数の長い脂肪酸を
供給し、これが乳児の脳の発育に重要な意義を持
つていることは明らかである。英国の生化学者で
ある前記著者のCrawfordは“人工乳で哺育され
る乳児はその最も脳の発育に重要な期間に最良の
質として要求される大切な材料を拒まれている”
と指摘している（同著書第190頁）。Conventional technology The human brain develops rapidly from birth until the age of three.
It is said that the increase in brain weight is extremely slow after the age of five. It is well known that, unlike other organs, the human brain is made up of approximately 60% lipids on a dry weight basis. In addition, this lipid is used as an important component of the myelin sheath that protects the outside of the cranial nerves, and it is well known that the myelin sheath increases as the brain and spinal cord develop in higher animals. ing. Moreover, the results of animal tests suggest that there is a deep relationship between myelination and learning ability [Yuzo Tsukada: Nippon Iji Shinpo 1975 No. 2684, pp. 126-127; Shuzo Naka: Brain marrow Functions and Education (published by Keio Tsushin in 1972) No. 200-201
page〕. Lipids, which are the main components of this brain marrow, are extremely rich in fatty acids with long carbon numbers that cannot be found in plants. In particular, 40 to 50% of the fatty acids that make up phosphatidylethanolamine are unique to humans. It has been confirmed that it is [M.
Crawford, translated by Hikoyuki Yamaguchi et al.: Eating habits and civilization (Yugakusha), pp. 40-46 (1980)]. Human breast milk supplies milk with almost undetectable long-carbon fatty acids, which clearly have important implications for infant brain development. The author Crawford, a British biochemist, said, ``Infants who are bottle-fed are denied the most important materials needed in the best possible quality during their most critical period for brain development.''
(Page 190 of the same book).
一方動物の脳髄、特に牛の脳髄各部の脂質の組
成については古くから研究されておりコレステリ
ン、糖脂質、燐脂質の分布が人脳と極めて類似し
ていることが報告されている〔西本順次郎：九州
神経精神医学第２巻第１号第39〜44頁（1951
年）〕。このようなことから牛脳中の有効成分を医
薬に応用しようとした試みも行われ、牛脳を膵臓
酵素で処理して得られたアミノ酸及びリポイドを
主成分とする抽出物にビタミン等を加えて製した
経口錠剤が精神薄弱児の精神発育遅滞及び脳溢血
後遺症の治療剤として市場に提供された〔佐藤時
治郎ほか：小児臨床第10巻第12号第1018〜1026頁
（1957年）〕。 On the other hand, the composition of lipids in various parts of the brain spinal cord of animals, especially cows, has been studied for a long time, and it has been reported that the distribution of cholesterin, glycolipids, and phospholipids is extremely similar to that in the human brain [Jun Nishimoto] Jiro: Kyushu Neuropsychiatry Vol. 2, No. 1, pp. 39-44 (1951)
Year)〕. For this reason, attempts have been made to apply the active ingredients in bovine brain to medicine, and vitamins, etc. are added to the extract, which is obtained by treating bovine brain with pancreatic enzymes and whose main components are amino acids and lipoids. Oral tablets prepared using this method were offered on the market as a treatment for mental retardation and sequelae of cerebral hemorrhage in mentally retarded children [Tokijiro Sato et al.: Children's Clinic, Vol. 10, No. 12, pp. 1018-1026 (1957)].
併しながら動物の脳髄を人工栄養児或は幼児の
脳の発育に必要な脂質の資源として食品として提
供しようとする試みは未だ実行されていない。 However, no attempt has yet been made to provide animal brain marrow as food to artificially fed infants or infants as a resource for the lipids necessary for brain development.
発明が解決しようとする問題点
動物の脳髄はその約60％が脂質であるためこれ
を通常の加熱乾燥手段で粉末状とすることは殆ん
ど不可能であり、かつ含水状態で加熱することは
脂質の分解を助長し、色調をも黒変させる。又含
水状態で細菌或はウイルスの繁殖し得る温度に長
時間置くことは極めて危険であるので、このよう
な温度での取扱いはこれを極度に少くする必要が
ある。更に脳髄を適当な基材と磨砕混合して希釈
し、乾燥を容易にしようとする場合には脳髄成分
の安定性に悪影響を与えず、かつ基材自身が乳幼
児の消化器に害を与えるものであつてはならな
い。本発明に従つて得られる製品は特に乳幼児に
適するものとして配慮されたことを強調したい。
本発明者らは以上のような制約のすべてを満足さ
せ、かつ食品としての商品価値を有する脳髄乾燥
物を得る方法について研究した結果、本発明の方
法を見出すに至つたものである。Problems to be Solved by the Invention Since animal brain marrow is approximately 60% lipid, it is almost impossible to turn it into a powder using normal heating and drying methods, and it is difficult to heat it in a water-containing state. promotes the decomposition of lipids and also turns the color black. Furthermore, it is extremely dangerous to leave the product in a water-containing state for a long time at a temperature where bacteria or viruses can propagate, so handling at such temperatures must be minimized. Furthermore, when attempting to dilute the brain marrow by grinding and mixing it with a suitable base material to facilitate drying, the stability of the brain marrow components is not adversely affected, and the base material itself is harmful to the digestive system of infants. It should not be a thing. We would like to emphasize that the products obtained according to the invention have been particularly considered to be suitable for infants and young children.
The present inventors conducted research on a method for obtaining a dried brain marrow that satisfies all of the above-mentioned constraints and has commercial value as a food product, and as a result, they discovered the method of the present invention.
問題点を解決するための手段
本発明者らは牛脳を磨砕したのちグルコン酸カ
ルシウム等の有機酸カルシウムと共に練和し、又
は更に磨砕し、そののち凍結させ、これを冷凍乾
燥法により乾燥すると、得られた乾燥物は容易に
粉末化し得ることを見出したことにより、これを
乳幼児の脳の順調な発育を助けるための食品とし
て、或は薬品として提供し得ることを明らかにし
た。即ち得られた有機酸カルシウム含有牛脳粉末
は淡黄色の粉末であつて80℃以上100℃以下の短
時間の加熱によつても変色せず、これを例えば牛
乳中に懸濁して乳児に与えることが可能であり、
又乳児用ビスケツト粉末と混合して加圧成形して
ビスケツト様の乳幼児用食品とすることも容易で
ある。本発明において希釈用基材として使用する
有機酸カルシウムはグルコン酸、クエン酸、乳
酸、酒石酸、リンゴ酸、コハク酸、酢酸を包含す
る有機酸のカルシウム塩が適しており、特にその
溶液が抗アレルギー剤として静脈注射にも使用さ
れ、かつ食品添加物として使用されるグルコン酸
カルシウム、カルシウム補強の目的に食品添加物
として使用されるクエン酸カルシウム及び乳酸カ
ルシウムは最も好適に使用される。有機酸カルシ
ウムの使用量は牛脳を例にとれば新鮮牛脳重量の
５％以上で使用することが必要であつて40％程度
の使用も可能であるが、乾燥物の粉末化の容易性
竝びに経済的見地よりすれば１〜20％を用いるこ
とが特に適している。また牛脳乾燥物にビタミン
剤の如き食品添加物として認可されている栄養物
を添加補強することも本発明の応用例として考慮
される。Means for Solving the Problems The present inventors ground bovine brain, kneaded it with organic acid calcium such as calcium gluconate, or ground it further, then frozen it, and freeze-dried it by freeze-drying. By discovering that the obtained dried product can be easily powdered when dried, it has become clear that it can be provided as a food or medicine to support the smooth development of infants' brains. That is, the obtained bovine brain powder containing organic acid calcium is a pale yellow powder that does not change color even when heated for a short time above 80°C and below 100°C, and can be suspended in milk and given to infants. It is possible to
It is also easy to mix it with infant biscuit powder and press-mold it to make a biscuit-like infant food. In the present invention, calcium salts of organic acids including gluconic acid, citric acid, lactic acid, tartaric acid, malic acid, succinic acid, and acetic acid are suitable as the organic acid calcium used as the base material for dilution, and in particular, the solution thereof is anti-allergic. Calcium gluconate, which is also used as a food additive for intravenous injection, and calcium citrate and calcium lactate, which are used as food additives for the purpose of calcium reinforcement, are most preferably used. Taking bovine brain as an example, the amount of organic acid calcium used must be at least 5% of the weight of fresh bovine brain, and it is possible to use about 40%, but the ease of powdering the dried product is From an economic point of view, it is particularly suitable to use 1 to 20% for eyelashes. Further, supplementing the dried bovine brain with nutrients approved as food additives such as vitamins may also be considered as an application example of the present invention.
作 用
家畜の脳髄を食用とすることは世界的に一般に
行われており、本邦でも新鮮なものにシヨウガ、
ゴマなどを混ぜて揚げものとしたり、ソーセージ
などの原料としている〔大川徳太郎ほか：食品材
料学（医歯薬出版発行、四訂）第45〜46頁（1981
年）〕。併しながら家畜の脳髄の特有な成分である
脳脂質は成人よりも脳の発育期にある乳児及び３
才までの幼児において特に貴重であり、これを乳
幼児が容易に摂取できるか、或は好んでこれを摂
取することができる形態で提供することが本発明
の目的であり、かつ本発明により始めて可能とな
つたものである。Effects Eating the brain marrow of livestock is a common practice around the world, and even in Japan, fresh ones such as ginger, ginger, etc.
It is mixed with sesame seeds and other ingredients to make fried foods, and is used as a raw material for sausages, etc. [Tokutaro Okawa et al.: Food Materials Science (Ishiyaku Publishing, 4th edition), pp. 45-46 (1981)
Year)〕. However, brain lipids, which are unique components of the brain spinal cord of livestock, are more concentrated in infants and adults whose brains are still developing than in adults.
It is an object of the present invention to provide this product in a form that infants can easily or prefer to ingest, which is particularly valuable for infants up to the age of 10. It has become.
本発明の方法によつて製造される脳髄粉末製品
の他の特徴は天然のバランスをもつて含有されて
いる微量の金属元素である。人工乳で哺育を行う
場合の問題点の一つは粉乳中の微量金属、特に亜
鉛及び銅の含量が母乳と比較して著しく低いこと
で、この事は乳児の発育に及ぼすマイナス因子と
して憂慮されている〔山本良郎ほか：小児科第22
巻第1477〜1489頁（1981年）〕。脳の中の微量金属
は代謝に重要な役割をもつていることが知られて
おり、例えば牛脳中に見出される銅を結合した２
種の蛋白はそれぞれ異つた酵素作用を呈すること
が認められている〔S.G.Sharoyanほか：
Biochimica et Biophisica Acta第493号第478〜
487頁（1977年）〕。 Another feature of the brain marrow powder product produced by the method of the invention is the naturally balanced content of trace metal elements. One of the problems with formula-feeding is that the content of trace metals, especially zinc and copper, in powdered milk is significantly lower than in breast milk, and this is a concern as a negative factor for infant growth. [Yoshiro Yamamoto et al.: Pediatrics No. 22]
Volume No. 1477-1489 (1981)]. Trace metals in the brain are known to play an important role in metabolism; for example, trace metals found in cow brain,
It is recognized that different species of proteins exhibit different enzymatic actions [SGSharoyan et al.
Biochimica et Biophisica Acta No. 493 No. 478~
487 pages (1977)].
実施例 次に本発明の方法を実施した例を示す。Example Next, an example in which the method of the present invention was implemented will be shown.
例 １
屠場で採取した新鮮牛脳５個を滅菌水で洗い、
脳膜及び血管を除去し、再度滅菌水で洗う。これ
を乳鉢中で磨砕して秤量し970ｇを得た。これに
グルコン酸カルシウム97ｇを加えて乳鉢中で均一
に練和し直ちに凍結乾燥器中で凍結させたのち高
度真空下で乾燥する。得られた乾燥物の収量は
317ｇであり、乾燥物中の牛脳は69.4％、グルコ
ン酸カルシウムは30.6％に相当する。この乾燥物
は乳鉢又は衝撃式粉砕機により容易に淡黄色の粉
末となる。かくして得た粉末牛脳を80゜以上100℃
以下に30分間加熱して製品とする。本品は適量を
そのまま牛乳又は粉乳に混じて乳児に与える。ま
たこの乾燥牛脳粉末に５〜６倍量の乳児用ビスケ
ツト粉末を混和して適宜の大きさに成形すれば乳
幼児の嗜好に適する栄養食品が得られる。Example 1 Five fresh cow brains collected at a slaughterhouse were washed with sterile water,
The brain membranes and blood vessels are removed and washed again with sterile water. This was ground in a mortar and weighed to obtain 970 g. 97 g of calcium gluconate was added thereto, kneaded uniformly in a mortar, immediately frozen in a freeze dryer, and then dried under a high vacuum. The yield of the dry matter obtained is
It is 317g, which corresponds to 69.4% of bovine brain and 30.6% of calcium gluconate in the dry matter. This dried product is easily turned into a pale yellow powder in a mortar or impact mill. The thus obtained powdered beef brain was heated at a temperature of 80° or more to 100°C.
Heat the product for 30 minutes as follows. Give an appropriate amount of this product to infants by mixing it with milk or powdered milk. Furthermore, if this dried beef brain powder is mixed with 5 to 6 times the amount of infant biscuit powder and molded into an appropriate size, a nutritional food suitable for infants' tastes can be obtained.
例 ２
新鮮な牛脳５個を滅菌水で洗い、脳膜及び血管
を除去し、再度滅菌水で洗う。これを乳鉢中で磨
砕して秤量し、990ｇを得た。これにクエン酸カ
ルシウム99ｇを添加して均一に練和し、直ちに例
１と同様の操作により牛脳凍結乾燥物297.7ｇを
得た。この乾燥物は例１と同様の淡黄色の粉末と
なり、牛乳又は粉乳に混じて乳児に与えられるほ
か例１と同様なビスケツト粉末との混合成形によ
り、又溶融チヨコレート中に30〜60％混和後に冷
却成形することにより乳幼児の嗜好に適する栄養
食品が得られる。Example 2 Wash five fresh bovine brains with sterile water, remove the brain membranes and blood vessels, and wash again with sterile water. This was ground in a mortar and weighed to obtain 990 g. 99 g of calcium citrate was added thereto and kneaded uniformly, followed by the same procedure as in Example 1 to obtain 297.7 g of lyophilized bovine brain. This dried product becomes a pale yellow powder similar to Example 1, and can be given to infants by mixing with milk or powdered milk, or by mixing and molding with biscuit powder as in Example 1, or after mixing 30 to 60% in molten tyokolate. By cooling and molding, a nutritional food suitable for the tastes of infants and young children can be obtained.
発明の効果
本発明の製造法に従えば目的製品を黒変させる
ことなく安定な淡黄色粉末として与えることがで
きる。Effects of the Invention According to the production method of the present invention, the desired product can be provided as a stable pale yellow powder without turning black.
本発明の方法によつて製造される動物の脳髄乾
燥物は乳幼児の脳の発育の為の脂質資源としての
みならず、天然のバランスをもつて含有されてい
る微量金属の資源としても乳幼児の消化器に害を
及ぼすことなく役立つことが期待される。また脳
髄の粉末化基材として使用する有機酸カルシウム
は吸収され易いカルシウム源として合せて期待で
きる。 The dried animal brain marrow produced by the method of the present invention not only serves as a lipid resource for infant brain development, but also as a resource for trace metals contained in a natural balance. It is hoped that it will be useful without causing any harm to the vessel. In addition, organic acid calcium used as a powdered base material for brain marrow can also be expected to be an easily absorbed calcium source.
Claims (1)
％、好ましくは10〜20％に相当する有機酸カルシ
ウムを加えて均一に練和し、これを冷凍乾燥した
のち粉砕することを特徴とする脳髄粉末の製造
法。 ２ 有機酸カルシウムがグルコン酸カルシウム、
乳酸カルシウム、クエン酸カルシウム、酒石酸カ
ルシウム、リンゴ酸カルシウム、コハク酸カルシ
ウム、酢酸カルシウムを包含する有機酸カルシウ
ムからなる群から選ばれる特許請求の範囲第１項
記載の脳髄粉末の製造法。[Claims] 1. Grind the brain marrow of an animal, and add 5 to 40
%, preferably 10 to 20%, is uniformly kneaded, freeze-dried, and then pulverized. 2 Organic acid calcium is calcium gluconate,
2. The method for producing brain marrow powder according to claim 1, which is selected from the group consisting of organic acid calcium including calcium lactate, calcium citrate, calcium tartrate, calcium malate, calcium succinate, and calcium acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60169170A JPS6229951A (en) | 1985-07-31 | 1985-07-31 | Production of encephalon powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60169170A JPS6229951A (en) | 1985-07-31 | 1985-07-31 | Production of encephalon powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6229951A JPS6229951A (en) | 1987-02-07 |
| JPS6345792B2 true JPS6345792B2 (en) | 1988-09-12 |
Family
ID=15881553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60169170A Granted JPS6229951A (en) | 1985-07-31 | 1985-07-31 | Production of encephalon powder |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6229951A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2714574B1 (en) * | 1993-12-31 | 1996-03-15 | Inst Rech Biolog Sa | New food supplements for the nutrition of very young children. |
| FR2721516B1 (en) * | 1994-06-27 | 1996-09-13 | Inst Rech Biolog Sa | New uses of a complex based on brain phospholipids in therapy and in food. |
| JP4203555B2 (en) * | 2000-04-14 | 2009-01-07 | 奥野製薬工業株式会社 | Boiled meat quality improvement method |
-
1985
- 1985-07-31 JP JP60169170A patent/JPS6229951A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6229951A (en) | 1987-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1989000011A1 (en) | Process for producing food | |
| CN102379441A (en) | Peanut and brown rice milk beverage and production technique thereof | |
| JPH06237734A (en) | Food composition for hypofunctional disease | |
| KR102234999B1 (en) | Health food manufacturing method based on edible insects and health food manufactured by the same | |
| US2659676A (en) | Infant food | |
| JPS6345792B2 (en) | ||
| JPS6159290B2 (en) | ||
| CN1149967A (en) | Beestings recombined health beverage | |
| JPS6365285B2 (en) | ||
| DE3422466C1 (en) | Process for producing an edible, protein-containing bonemeal preparation from fresh animal bones | |
| JP3366769B2 (en) | Nutritional composition containing milt | |
| CN109329776A (en) | A kind of shortening liquid meat and preparation method thereof | |
| CN111802576A (en) | Chinese yam nutritional noodles for infants and preparation method thereof | |
| AU2020102693A4 (en) | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof | |
| RU2181019C2 (en) | Canned meat for curative-prophylactic nutrition | |
| JPS63109737A (en) | Spread-like food | |
| JP2521068B2 (en) | healthy food | |
| RU2197153C2 (en) | Method of producing preserves on base of poultry meat for prophylactic alimentation | |
| RU2300905C1 (en) | Meat-based product for enteral feeding of tender age infants | |
| RU2108726C1 (en) | Method for production of dietary cultured milk product | |
| JP2001029011A (en) | Nutrient composition | |
| JP3921575B2 (en) | Cheese starter manufacturing method | |
| RU2073464C1 (en) | Method for production of food product containing jelly-forming agent | |
| RU2246236C9 (en) | Meat-based composition for producing of baby foods | |
| KR101377262B1 (en) | Manufacturing method of seafood icecream |